Continous Positive Airway Pressure (CPAP) Support for Acute Hypoxemic Respiratory Failure in Burkina Faso
NCT ID: NCT06912360
Last Updated: 2025-07-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
240 participants
INTERVENTIONAL
2025-07-09
2026-02-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Used of Boussignac-type CPAP could potentially reduce the recourse to intubation in patients with acute hypoxemic respiratory failure in a context where access to invasive ventilation remains very limited.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Acute Respiratory Intervention StudiEs in Africa (ARISE-AFRICA) Study
NCT04693403
Post-extubation Nasal Humidified High-flow Oxygen Versus Non-invasive Positive Pressure Ventilation
NCT06918288
CPAP Therapy Through a Helmet or a Full Face Mask in Patients With Acute Hypoxemic Respiratory Failure: Cross-over Study
NCT06113432
A New Portable Device for Non-invasive Ventilatory Support
NCT06716502
Sigh in Acute Hypoxemic Respiratory Failure
NCT03201263
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The use of Boussignac-type CPAP could reduce the need for intubation in patients with acute respiratory failure in a setting where access to invasive ventilation remains very limited.
2. Objectives
2.1 Primary Objective
The primary objective is to evaluate the effect of CPAP use on the occurrence of intubation criteria at 7 days in patients presenting with ARF in the emergency department.
2.2 Secondary Objectives
The secondary objectives are:
* To assess the impact of CPAP use on 28-day mortality in patients with ARF
* To assess the effectiveness of CPAP use on oxygenation in patients with ARF using the SpO2/FiO2 ratio
* To assess the impact of CPAP use on hospital stay
* To assess the safety of CPAP in patients with ARF
2.3 Ancillary Studies
The ancillary studies are:
* To assess the contribution of ultrasound in the management of ARF
* To determine the etiologies and prognosis of ARF
* To determine the etiologies and prognosis of patients with ARDS in intensive care
* To assess the cost of ARF management
3. Methodology 3.1 Study Setting
The Study will take place in the four adult university hospitals in Burkina Faso. Patient recruitment will take place during the same period in the emergency and intensive care departments. Patient inclusion in each hospital will be under the responsibility of an emergency department physician or an anesthesiologist-intensive care physician.
3.2 Study Type
This will be an open-label, multicenter, national randomized clinical trial. The type of oxygenation device does not allow for a blinded study.
3.3 Study Designs
Within 3 hours of validating the inclusion criteria, patients will be assigned to one of the two groups after signing the consent form.
* In both groups, the oxygen flow will be adjusted to achieve an SpO2 of 92% or higher. SpO2 will be measured either using a monitor with integrated SpO2 measurement or using a portable device such as the Lifebox. The remainder of the patient's care will be administered according to the etiology of the ARF at the physician's discretion and according to recommandations. Any omission from the administration of study treatment will be noted on the collection sheet.
* In the standard group Patients assigned to the standard treatment group will receive oxygen delivered via nasal prongs, simple face masks, or a high-concentration face mask (as needed) until intubation criteria are met, death occurs, or oxygen discontinuation criteria are met (an SpO2 greater than 92% without oxygen and a respiratory rate less than 25 breaths/min).
Patients who meet the intubation criteria will either be intubated if a bed and a ventilator are available in intensive care, or may receive, at the discretion of the physician, CPAP treatment as backup treatment in crossover, if invasive ventilation is not possible.
\- In the CPAP group Patients assigned to the CPAP plus oxygen group will receive periods of CPAP in addition to standard oxygen therapy. All study centers will use a Boussignac device connected to an oronasal mask consisting of a transparent mask and a soft inflatable cushion. The CPAP pressure level will be determined by the oxygen flow rate according to the correlation table. CPAP will start at 7.5 cmH2O (i.e., a Boussignac supply of 25 L/min). The pressure level will be decreased to 5 cmH2O (i.e., a Boussignac supply of 20 L/min) or increased to 10 cmH2O (i.e., a Boussignac supply of 30 L/min) depending on clinical response and tolerance. For at least the first 6 to 12 hours, CPAP will be administered continuously, then intermittently (for at least 6 hours/day) depending on patient tolerance. CPAP will be continued until endotracheal intubation criteria are met, death occurs, or treatment is discontinued according to the following criteria: SpO2 greater than 92% and respiratory rate less than 25 breaths/min with 3 L of oxygen or less between CPAP sessions. The criteria for discontinuing oxygen administration will be the same as in the standard group.
Patients who meet the intubation criteria will either be intubated if a bed and ventilator are available in intensive care, or will continue CPAP treatment if invasive ventilation is not possible.
3.4 Stratification
Randomization will be stratified by study center and baseline hypoxemia status. Stratification block randomization will be performed using a centralized, secure electronic system.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CPAP group
Continuous CPAP (with Boussignac valve) for the first 6-12 hours, then alternating with standard oxygen therapy. CPAP pressure= 7.5 cmH2O (25L/min) then variations of +/- 2.5 cmH20 according to clinical response and tolerance until weaning from oxygen or presence of intubation criteria
CPAP
Continuous Positive Airway Pressure (CPAP) with Boussignac valve
Standard group
Oxygen therapy as required using, simple face masks or high concentration face masks until there are criteria for intubation, or withdrawal from oxygen.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CPAP
Continuous Positive Airway Pressure (CPAP) with Boussignac valve
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Acute respiratory distress, defined as dyspnea respiratory rate ≥ 25 cycles/min
* Hypoxemia, defined as the need for more 6 liters of oxygen to maintain an oxygen saturation (SpO2) of ≥ 92%. The fraction of inspired oxygen (FiO2) will be estimated using the 3% rule.
Exclusion Criteria
* Pregnant or breastfeeding women
* Persons deprived of their liberty
* Exacerbation of asthma, chronic obstructive pulmonary disease, or another chronic respiratory disease
* Moderate to large amount of unilateral or bilateral undrained pleural effusion
* Contraindication to CPAP: patient refusal, undrained pneumothorax, chest injury, repeated or large vomiting, upper gastrointestinal bleeding, craniofacial trauma, severe upper airway obstruction, or tetraplegia in the initial phase
* Cardiac arrest, severe arrhythmias, shock requiring the use of vasopressors (norepinephrine, adrenaline, dopamine)
* Altered level of consciousness (Glasgow Coma Scale score \< 13), repeated seizures, or status epilepticus
* Medical decision to limit treatment: no intubation, no admission to intensive care
* Refusal to participate in the study or participation in another interventional study on respiratory distress or acute respiratory failure.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique - Hôpitaux de Paris
OTHER
Université NAZI BONI
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ismael Guibla
Clinical doctor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Armand Mekontso-dessap, professor
Role: STUDY_CHAIR
Assistance Publique - Hôpitaux de Paris
Ismael Guibla, doctor
Role: PRINCIPAL_INVESTIGATOR
University Hospital Souro Sanou, Burkina Faso
Ibrahim Alain Traore, professor
Role: STUDY_DIRECTOR
University Hospital Souro Sanou, Burkina Faso
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalier Universitaire Souro Sanou
Bobo-Dioulasso, Houet, Burkina Faso
CHU Yalgado Ouedraogo
Ouagadougou, Kadiogo, Burkina Faso
CHU Tengandogo
Ouagadougou, Kadiogo, Burkina Faso
CHU Bogodogo
Ouagadougou, Kadiogo, Burkina Faso
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Markou NK, Myrianthefs PM, Baltopoulos GJ. Respiratory failure: an overview. Crit Care Nurs Q. 2004 Oct-Dec;27(4):353-79. doi: 10.1097/00002727-200410000-00006.
Stefan MS, Shieh MS, Pekow PS, Rothberg MB, Steingrub JS, Lagu T, Lindenauer PK. Epidemiology and outcomes of acute respiratory failure in the United States, 2001 to 2009: a national survey. J Hosp Med. 2013 Feb;8(2):76-82. doi: 10.1002/jhm.2004. Epub 2013 Jan 18.
SRLF Trial Group. Hypoxemia in the ICU: prevalence, treatment, and outcome. Ann Intensive Care. 2018 Aug 13;8(1):82. doi: 10.1186/s13613-018-0424-4.
Perkins GD, Ji C, Connolly BA, Couper K, Lall R, Baillie JK, Bradley JM, Dark P, Dave C, De Soyza A, Dennis AV, Devrell A, Fairbairn S, Ghani H, Gorman EA, Green CA, Hart N, Hee SW, Kimbley Z, Madathil S, McGowan N, Messer B, Naisbitt J, Norman C, Parekh D, Parkin EM, Patel J, Regan SE, Ross C, Rostron AJ, Saim M, Simonds AK, Skilton E, Stallard N, Steiner M, Vancheeswaran R, Yeung J, McAuley DF; RECOVERY-RS Collaborators. Effect of Noninvasive Respiratory Strategies on Intubation or Mortality Among Patients With Acute Hypoxemic Respiratory Failure and COVID-19: The RECOVERY-RS Randomized Clinical Trial. JAMA. 2022 Feb 8;327(6):546-558. doi: 10.1001/jama.2022.0028.
Templier F, Dolveck F, Baer M, Chauvin M, Fletcher D. [Laboratory testing measurement of FIO2 delivered by Boussignac CPAP system with an input of 100% oxygen]. Ann Fr Anesth Reanim. 2003 Feb;22(2):103-7. doi: 10.1016/s0750-7658(02)00859-6. French.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
INSSA 4
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.